7,649+ stem cell transplants since 1984, 140+ paediatric stem cell transplants annually, treating sickle cell disease, thalassaemia, leukaemia, lymphoma and myeloma.
Yes. Submit your full blood panel, bone marrow biopsy, cytogenetics, and molecular studies for a remote assessment before you commit to travel.
You receive a written clinical evaluation confirming your case fit and the specialist team assigned.
Send reports via WhatsApp at +1 718 550 0880 or email [email protected].
Yes. KFSH&RC is the only centre in the Arab world with an in-house CAR-T manufacturing facility.
T-cells are harvested, genetically modified, and reinfused on site.
Since 2020, 200+ patients have received in-house CAR-T therapy with manufacturing time reduced by 50%.
The programme covers B-cell lymphomas, ALL, and multiple myeloma.
Yes. The paediatric programme runs through King Fahad National Centre for Children's Cancer on the Riyadh campus, accredited by the Children's Oncology Group.
It performs 140+ paediatric stem cell transplants annually with a 92% five-year survival rate for childhood ALL.
Conditions include leukaemia, lymphoma, sickle cell disease, thalassaemia, aplastic anaemia, and rare inherited bone marrow disorders.
Haematology consultations and treatment coordination at KFSH&RC are managed through the International Patient Care Centre.
Available 24/7 for online consultations, remote report reviews, and full coordination with your assigned haematologist.
Stay length depends on your procedure, your condition and how you recover. Your coordinator gives you a written itinerary with the expected stay for your case before you book flights.
The international patient team books accommodation near the hospital at no cost for the booking service, with options to suit your preference and budget, including space for a caregiver.
This combination of four accreditations is held by fewer than a handful of centres globally, confirming KFSH&RC meets the highest standards for transplant outcomes, data reporting, and protocol compliance.
KFSH&RC treats sickle cell disease with stem cell transplant as a curative option, thalassaemia requiring transplant evaluation, relapsed or refractory leukaemia or lymphoma with CAR-T therapy, and aplastic anaemia or MDS with allogeneic transplant.
KFSH&RC is the only centre in the Arab world manufacturing CAR-T cell therapy in-house.
Patients travelling from outside the GCC receive a Medical Referral Letter for their Saudi visa application, help with flights and accommodation, and Arabic and English coordination.